Half-life
1.2 days
ATTAIN-1 Phase III (non-diabetic obese): 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg. 59.6% achieved ≥10% weight loss, 39.6% achieved ≥15% weight loss. ATTAIN-2 (T2DM): 10.5% weight loss. Superior to all existing oral obesity medications.
Non-peptide small molecule GLP-1R agonist (Eli Lilly). Biased signaling: preferential G protein/cAMP pathway activation → insulin secretion, glucagon suppression, gastric emptying delay, appetite reduction — while minimizing receptor desensitization. Half-life 29–49 hours. 79.1% oral bioavailability vs ~1% for oral peptide GLP-1 agonists.
79.1% oral bioavailability; 12.4% weight loss Phase III ATTAIN-1; 29–49h half-life; oral GLP-1R agonist; superior to existing oral obesity drugs; FDA-approved Apr 1 2026 as Foundayo (NDA 220934) for obesity/overweight.
Research data is not a treatment plan. If you are considering Orforglipron, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.
Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.Interactive tools for this compound:
Reconstitution calculator · Full deep dive · Peptide fundamentals